Steven O’Day shared the latest data and insights from our botensilimab programs – Agenus

Agenus shared on LinkedIn:

“Yesterday, our Chief Medical Officer, Dr. Steven O’Day, joined clinical experts and researchers at Nature Portfolio’s Cancer Immunotherapy conference in Boston, where he shared the latest data and insights from our botensilimab programs.

Thank you to all participants for the impactful discussion as we work together to advance the field of immunotherapy.”.

Source: Agenus/LinkedIn